Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-04-05
2011-04-05
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100, C424S133100, C424S141100, C424S178100, C530S387100, C530S388100, C530S391100
Reexamination Certificate
active
07919594
ABSTRACT:
Compositions and methods are provided for treating diseases associated with CD100, including certain types of cancers, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejections, and invasive angiogenesis. Compositions include anti-CD100 antibodies capable of binding to a soluble human CD100 antigen or a CD100 antigen located on the surface of a human CD100-expressing cell, wherein the antibody has CD100 blocking activity that is achieved by having at least one optimized CDR or FWR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD100 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD100 antibodies.
REFERENCES:
patent: 6576754 (2003-06-01), Hall et al.
patent: 2003/0158402 (2003-08-01), Hall et al.
patent: 2006/0233793 (2006-10-01), Belin et al.
patent: WO 93/14125 (1993-07-01), None
patent: WO 95/07706 (1995-03-01), None
patent: WO 97/17368 (1997-05-01), None
patent: WO 2004/067034 (2004-08-01), None
patent: WO 2006/110594 (2006-10-01), None
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from it's receptor-binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation fo aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Scholm, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Reff and Heard. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Critical Reviews in Oncology/ Hematology, 2001. vol. 40, pp. 25-35.
Basile, J., et al., “Semaphorin 4D Provides a Link Between Axon Guidance Processes and Tumor-Induced Angiogenesis,”Proc. Nat'l. Acad. Sci. USA, 2006, pp. 9017-9022, vol. 103(24).
Billard, C., et al. “Switch in the Protein Tyrosine Phosphatase Associated with Human CD100 Semaphorin at Terminal B-Cell Differentiation Stage,”Blood, 2000, pp. 965-972, vol. 95(3).
Bougeret, C., et al., “Increased Surface Expression of a Newly Identified 150-kDa Dimer Early After Human T Lymphocyte Activation,”The Journal of Immunology, 1992, pp. 318-323, vol. 148(2).
Claesson-Welsh, L., “Novel Paths to Blood Vessel Formation,”Blood, 2005, pp. 4153-4154, vol. 105(11).
Conrotto, P., et al., “Sema4D Induces Angiogenesis Through Met Recruitment by Plexin B1,”Blood, 2005, pp. 4321-4329, vol. 105(11).
Deaglio, S., et al., “CD38 and CD100 Lead a Network of Surface Receptors Relaying Positive Signals for B-CLL Growth and Survival,”Blood, 2005, pp. 3042-3050, vol. 105(8).
Delaire, S., et al., “Biological Activity of Soluble CD100. II. Soluble CD100, Similarly to H-SemaIII, Inhibits Immune Cell Migration,”The Journal of Immunology, 2001, pp. 4348-4354, vol. 166.
Delaire, S., et al., “Inhibition of Immune Cell Migration by Soluble CD100 and H-Sema III Semaphorins,”Tissue Antigens, 2000, p. 103, vol. 55(Supp. 1).
Elhabazi, A., et al., “Biological Activity of Soluble CD100. I. The Extracellular Region of CD100 is Released from the Surface of T Lymphocytes by Regulated Proteolysis,”The Journal of Immunology, 2001, pp. 4341-4347, vol. 166.
Elhabazi, A., et al., “The Human Semaphorin-Like Leukocyte Cell Surface Molecule CD100 Associates with a Serine Kinase Activity,”The Journal of Biological Chemistry, 1997, pp. 23515-23520, vol. 272(38).
Elhabazi, A., et al., “Structure and Function of the Immune Semaphorin CD100/SEMA4D,”Critical View™ in Immunology, 2003, pp. 65-81, vol. 23(1&2).
Fishwild, D.M., et al., “High-Avidity Human IgGκ Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice,”Nature Biotechnology, 1996, pp. 845-851, vol. 14.
Gauld, S., et al., “B Cell Antigen Receptor Signaling: Roles in Cell Development and Disease,”Science, 2002, pp. 1641-1642, vol. 296.
Giraudon, P., et al., “Semaphorin CD100 from Activated T Lymphocytes Induces Process Extension Collapse in Oligodendrocytes and Death of Immature Neutral Cells,”Journal of Immunology, 2004, pp. 1246-1255, vol. 172(2).
Hall, K., et al., “Human CD100, A Novel Leukocyte Semaphorin That Promotes B-Cell Aggregation and Differentiation,”Proc Natl Sci USA, 1996, pp. 11780-11785, vol. 93.
Herold, C., et al., “Activation Signals Are Delivered Through Two Distinct Epitopes of CD100, A Unique 150 kDa Human Lymphocyte Surface Structure Previously Defined by BB18 mAb,”International Immunology, 1995, pp. 1-8, vol. 7(1).
Herold, C., et al., “CD100 Defines a Newly Identified 150-kDa Human Lymphocyte Surface Structure,” 1994, In Schlossman, S. et al., eds.Leukocyte Typing V, Section T, Oxford University Press, Oxford.
Ishida, L., et al., “Involvement of CD100, A Lymphocyte Semaphorin, in the Activation of the Human Immune System Via CD72: Implications for the Regulation of Immune and Inflammatory Responses,”International Immunology, 2003, pp. 1027-1034, vol. 15(8).
Kruger, R.P., et al., “Semaphorins Command Cells to Move,”Nature Reviews Molecular Cell Biology, 2005, pp. 789-800, vol. 6.
Kumanogoh, A., and H. Kikutani, “The CD100-CD72 Interaction: A Novel Mechanism of Immune Regulation,”Trends in Immunology, 2001, pp. 670-676, vol. 22(12).
Kumanogoh, A., et al., “Class IV Se
Fisher, Jr. Terrence Lee
Smith Ernest S.
Zauderer Maurice
Alston & Bird LLP
Gussow Anne M.
Vaccinex, Inc.
LandOfFree
Human anti-CD100 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human anti-CD100 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human anti-CD100 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2722721